The project has received funding from the European Union’s HORIZON 2022
research and innovation funding programme under Agreement No 881101.
Learn about our system
BacterOMIC is a diagnostic system designed to address one of the most important challenges in modern medicine – multidrug resistance.
BacterOMIC consists of an Analyzer, Filling Device, and Panels for drug susceptibility assessment. As an automated system, it significantly simplifies and shortens laboratory procedures used in the evaluation of drug susceptibility of microorganisms.
The system allows phenotypic evaluation of the efficacy of 25 antibiotics used to treat respiratory, blood, urinary tract, or skin infections, among others.
Owing to the determination and expertise of a team of biotechnologists, engineers and software developers, and an innovative approach to the problem of modern diagnostics, a device has been created with considerable market potential and offering to revolutionize antibiotic treatment.
The BacterOMIC system has obtained European CE IVD certification granting it approval for sale on the European Union market.
The BacterOMIC project received from CeCert Sp. z o. o. the certificate of compliance with the ISO 13485:2016-04 standard.
BACTEROMIC Sp. z o.o.
The BacterOMIC system has been developed by the Scope Fluidics Group, which develops innovative medical diagnostic devices as part of its special purpose vehicle Bacteromic sp. z o.o.
Meet the Management Board of Bacteromic sp. z o.o.
BacterOMIC
BacterOMIC
A unique diagnostic solution
For doctors and patients
Strengths
Procedure for Use
Tests carried out in specialist diagnostic centres have confirmed the functionality of the BacterOMIC system in effectively identifying drug susceptibility of bacteria causing a range of infections. As emphasized by doctors and experts at the World Health Organisation (WHO), antibiotic resistance is one of the most serious problems in modern medicine.
Procedure for Use
Isolated
bacterial strain
Monoculture
bacterial suspension
Transfer of suspension
to cartridge
Closure of cap
Placement of cartridges
in rack
Placement of
rack in
automatic filling unit
Single filling of up
to 10 cartridges
Transfer of filled
cartridges to Analyzer
Fully automated analysis
of up to 60 samples
BacterOMIC Analyzer
BacterOMIC Filling Device
BacterOMIC Diagnostic Panel
Effective antibiotic therapies
The BacterOMIC system enables single identification of the efficacy of a range of 25 antibiotics used in treatment of infections of the respiratory system, blood, urinary tract, or skin, among others. It is a rapid and accurate assessment of drug susceptibility of Gram-positive and Gram-negative bacteria in a single diagnostic panel.
BacterOMIC Panel UNI
Antibiotic
Microorganisms
Antibiotic
Microorganisms
Amikacin
Enterobacterales
Clarithromycin
Staphylococcus
Amoxicillin
Enterobacterales
Clindamycin
Enterococcus
Amoxicillin – clavulanic acid
Enterobacterales
Erythromycin
Enterococcus; Staphylococcus
Ampicillin
Enterobacterales
Gentamicin
Enterobacterales; Staphylococcus
Azithromycin
Staphylococcus
Levofloxacin
Acinetobacter; Enterobacterales; Enterococcus; Pseudomonas; Staphylococcus
Benzylpenicillin
Staphylococcus
Linezolid
Enterococcus; Staphylococcus
Cefazolin
Enterobacterales
Meropenem
Acinetobacter; Enterobacterales; Pseudomonas; Staphylococcus
Cefepime
Enterobacterales; Pseudomonas; Acinetobacter
Ofloxacin
Enterobacterales; Staphylococcus
Ceftazidime
Enterobacterales; Pseudomonas;
Tedizolid
Staphylococcus
Ceftazidime – Avibactam
Enterobacterales; Pseudomonas;
Tobramycin
Enterobacterales; Enterococcus; Pseudomonas
Ceftriaxone
Enterobacterales
Vancomycin
Enterococcus
Cefuroxime
Enterobacterales
Assessment of the presence of ESBL
Enterobacterales
Ciprofloxacin
Acinetobacter; Enterobacterales; Staphylococcus
Antibiotic
Amikacin
Amoxicillin
Amoxicillin – clavulanic acid
Ampicillin
Azithromycin
Benzylpenicillin
Cefazolin
Cefepime
Ceftazidime
Ceftazidime – Avibactam
Ceftriaxone
Cefuroxime
Ciprofloxacin
Microorganisms
Enterobacterales
Enterobacterales
Enterobacterales
Enterobacterales
Staphylococcus
Staphylococcus
Enterobacterales
Enterobacterales; Pseudomonas; Acinetobacter
Enterobacterales; Pseudomonas;
Enterobacterales; Pseudomonas;
Enterobacterales
Enterobacterales
Acinetobacter; Enterobacterales; Staphylococcus
Antibiotic
Clarithromycin
Clindamycin
Erythromycin
Gentamicin
Levofloxacin
Linezolid
Meropenem
Ofloxacin
Tedizolid
Tobramycin
Vancomycin
Assessment of the presence of ESBL
Microorganisms
Staphylococcus
Enterococcus
Enterococcus; Staphylococcus
Enterobacterales; Staphylococcus
Acinetobacter; Enterobacterales; Enterococcus; Pseudomonas; Staphylococcus
Enterococcus; Staphylococcus
Acinetobacter; Enterobacterales; Pseudomonas; Staphylococcus
Enterobacterales; Staphylococcus
Staphylococcus
Enterobacterales; Enterococcus; Pseudomonas
Enterococcus
Enterobacterales
Recipients
MICROBIOLOGY
LABORATORIES
CENTRAL
LABORATORIES
HOSPITALS
Technology
BacterOMIC is the world’s unique solution with the ultimate goal of being able to test as many as 640 bacterial culture conditions in a single test. This will translate into the capacity to compose a single test for the vast majority of clinically used antibiotics.
OUR PATENTS
Microfluidic chip
EP 3 546 067 B1
The invention is intended for microbiological testing cards, particularly for microbial identification and antimicrobial susceptibility testing (AST). It represents our core technology and protects the architecture of the microfluidic chip for microbiological testing. The European patent has been validated in 15 countries. In addition, in 2023 a patent for this invention issues in China. Patent application is still pending in the US.
Incubation segment with an unvented gas cavity in a microfluidic chip
EP 3 546 565 B1
The object of the invention is the geometry of a single incubation segment in a microfluidic chip, suitable for microbiological research. The European patent has been validated in 14 countries. Additionally, patent applications in the US and China are pending.
Method and system for rapidly testing antimicrobial susceptibility
EP 3 597 768 B1
The invention protects a rapid signal analysis method of determining the minimum inhibitory concentration (MIC) based on standard measurements in the shortest possible time to date. Using the method, system or application, it is possible to reduce the incubation time of a standard antimicrobial susceptibility test (AST) using broth dilution, or to increase the precision of qualitative or quantitative antimicrobial susceptibility determinations. Patents for the invention are in force in 14 European countries. In addition, two patent applications are pending in the US and China.
A syringe-plug and a cartridge for analytic assays comprising such a syringe-plug
WO 2022/243860 A1
The invention is a syringe-plug and a cartridge for analytic assays, in particular microbiological assays, including microbial identification and antimicrobial susceptibility testing (AST). Determination of antimicrobial resistance of many microbes requires culturing of said microbes, exposing them to defined agents and monitoring their growth. According to the invention a syringe-plug is provided for placement in a sample chamber of a cartridge for analytic assays, and it comprises a tank pre-filled with a non-aquatic liquid. International patent application is pending.
Method and system for prediction of microorganism growth using artificial intelligence
WO 2023/006967 A1
The invention relates to a computer-implemented method for real-time prediction of microorganism growth or growth inhibition of a microorganism inoculum using artificial intelligence (AI). This method relates in particular to a phenotypic antimicrobial susceptibility test (AST), as well as to a rapid antimicrobial susceptibility testing system. International patent application for this invention is pending.
Did you know…?
Follow our news stories!
Read about key stories in the development of our system.
Bacteromic is part of the
Scope Fluidics Group
We are developing the BacterOMIC project with a team of nearly 50 people working in a variety of specializations
E-MAIL US
